The Senate is currently considering legislation which would prohibit the FDA from including on FDA scientific advisory boards scientists "with industry ties" to drug manufacturers (the House already approved this legislation). Today, FDA's Dr. Scott Gottlieb emphatically opposed this proposed legislation, declaring that it would deprive FDA of advice from the best and brightest scientists in America.
Read the editorials written by ACSH president Dr. Elizabeth Whelan that comment on why ACSH applauds the FDA's position, and why we support the statement of FDA's Deputy Commissioner for Medical and Scientific Affair, Dr. Scott Gottleb:
b) FDA Says "Industry Ties" Not Sufficient Grounds to Keep Scientists Off Advisory Panels
c) FDA's Commonsense Position on "Conflict of Interest" Proposals for Advisory Boards
